Schulte Roth & Zabel represented lead financier Deep Track Capital in an investment in TORL BioTherapeutics, a clinical-stage biotechnology company involved in the discovery and development of immunotherapies designed to improve and extend the lives of patients with cancer worldwide.
The oversubscribed $158million Series B-2 financing spearheaded by Deep Track Capital, an investment firm focused exclusively on the life sciences industry, will advance a clinical-stage Antibody-Drug Conjugate.
The Schulte team was led by partner Michael Flynn and special counsel John Doherty.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.